While the immune system can eliminate cancer, it can also contribute to cancer growth under certain conditions. HMGB1 is an important immune molecule that plays a role in this process and may have immense value in the clinic. Dr. Bassi wants to understand more about its activity, so he’s analyzing tumor-immune interactions in a mouse cancer model and determining how differential HMGB1 activity influences breast cancer progression as well as responses to immunotherapy and chemotherapy. In this way, he hopes to reveal insights about new targets that guide new approaches to improve patient outcomes.
University Health Network (Canada) | Breast Cancer | 2016 | Tak W. Mak, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
We are Generation Cure. On June 11, we celebrated the ninth annual global immunotherapy awareness day to support a future immune to cancer.
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.